Sudeep Pharma's Stunning IPO Debut at ₹730
Sudeep Pharma made a dazzling entry into the Indian stock market on November 28, 2025, with its shares listing at ₹730 on the NSE. This represents a striking 23.10% premium over its IPO price of ₹593. The listing on BSE was even slightly higher at ₹733.95, showcasing a premium of 23.77%. This performance has delighted investors and surpassed market expectations.
The Sudeep Pharma IPO was highly anticipated, given the grey market premium (GMP) of ₹121 per share, which suggested a likely listing price around ₹714, translating to a premium of 20.40% over the upper end of the issue price band. The IPO opened for subscription on November 21 and closed on November 25, with allotments finalized by November 26. With a size of ₹895 crore, the IPO included a fresh issuance of 16 lakh shares worth ₹95 crore and an offer for sale (OFS) of 1.35 crore shares valued at ₹800 crore.
Promoters Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, and Sujeet Jaysukh Bhayani HUF are offloading part of their stake under the OFS. The IPO lot size was fixed at 25 shares, requiring a minimum investment of ₹14,825 at the upper end of the price band. The funds raised will be primarily used for capital expenditures, including ₹75.81 crore earmarked for procuring machinery for the production line at the company's Nandesari Facility I.
Sudeep Pharma's IPO saw exceptional subscription levels, with the overall issue subscribed 93.71 times. The retail portion was oversubscribed 15.65 times, while the non-institutional investors (NII) segment received 116.72 times bids, and Qualified Institutional Buyers (QIBs) segment was heavily oversubscribed at 213.08 times. This high demand reflects strong investor confidence in the company's growth prospects.
The company specializes in manufacturing specialty chemicals and ingredients, supplying high-value formulations to pharmaceutical, food, and nutrition companies worldwide. Its product portfolio aims to enhance quality and performance across various categories, positioning Sudeep Pharma as a key player in the specialty ingredients market.
Over the past year, Sudeep Pharma has shown steady growth, with revenue increasing from ₹459.28 crore in FY24 to ₹501.99 crore in FY25, a rise of about 9.3%. The total assets expanded significantly, reflecting a strong 39.6% jump, and net profit also improved by approximately 4.1%, indicating stable profitability. Investors are optimistic about the company's future, driven by its solid fundamentals and strategic investments.
